{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:01:19Z","timestamp":1776423679231,"version":"3.51.2"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016724","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","doi-asserted-by":"publisher","award":["71\/2-Edu-16\/608"],"award-info":[{"award-number":["71\/2-Edu-16\/608"]}],"id":[{"id":"10.13039\/100016724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016724","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","doi-asserted-by":"publisher","award":["INT\/IEC\/2020\/SPL-325"],"award-info":[{"award-number":["INT\/IEC\/2020\/SPL-325"]}],"id":[{"id":"10.13039\/100016724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["33\/29\/2019-TF\/Rare\/BMS DT"],"award-info":[{"award-number":["33\/29\/2019-TF\/Rare\/BMS DT"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IEC-11\/2019-1417"],"award-info":[{"award-number":["IEC-11\/2019-1417"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/8\/5\/2\/adhoc\/2020\/ECD-1"],"award-info":[{"award-number":["5\/8\/5\/2\/adhoc\/2020\/ECD-1"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["PGI\/IEC\/2020\/001070"],"award-info":[{"award-number":["PGI\/IEC\/2020\/001070"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic granulomatous disease (CGD) patients develop repeated infections and inflammatory complications. Underlying pathogenesis of hyperinflammation in CGD is not clearly characterized. To assess type-1 interferon signature and measure Siglec-1\/CD169 expression on monocytes in patients with CGD. mRNA sequencing of PBMCs in five CGD patients and three controls was analysed for differentially expressed genes. Subsequently, 20 patients with CGD, 10 heterozygous carriers of CYBB mutations, 11 healthy controls and 11 patients of systemic lupus erythematosus (disease controls) were enrolled. Expression of CD169 on monocytes was measured using flowcytometry. Expression of five type 1 interferon signature genes (ISGs) was measured using RT-PCR. On transcriptome analysis of peripheral blood mononuclear cells, increased expression of type-1 ISGs were seen in CGD patients. Monocyte CD169 expression was compared across three subgroups of CGD patients (10 = inflammatory disease, 5 = infectious disease, 5 = asymptomatic disease). CD169 expression on monocytes (percentage and \u0394MFI) was significantly high in inflammatory disease subgroup in comparison to asymptomatic disease subgroup of CGD (P = &amp;lt;0.001 and P = &amp;lt;0.001). Similarly, the expression was significantly high in inflammatory disease subgroup when compared to infection subgroup of CGD (P = 0.033 and P = 0.017). An elevated type-1 interferon score by RT-PCR was found in inflammatory disease subgroup in comparison to infection subgroup of CGD (P = 0.029) and healthy controls (P = 0.021). Percentage and \u0394MFI of monocyte CD169 correlated with type 1 interferon scores, rp = 0.38 (P = 0.049) and rp = 0.46 (P = 0.017), respectively. CGD patients with hyperinflammatory manifestations exhibited a high type 1 interferon signature. CD169 is a reliable surrogate marker for estimation of type 1 interferon signature.<\/jats:p>","DOI":"10.1093\/cei\/uxag003","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:18:06Z","timestamp":1768825086000},"source":"Crossref","is-referenced-by-count":0,"title":["Elevated type I interferon signature in patients with chronic granulomatous disease"],"prefix":"10.1093","volume":"220","author":[{"given":"Ridhima","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-5584","authenticated-orcid":false,"given":"Pandiarajan","family":"Vignesh","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Dod","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Leprosy, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-2532","authenticated-orcid":false,"given":"Saniya","family":"Sharma","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Rawat","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research , Chandigarh 160012 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026041706065532400_uxag003-B1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2017.02.029","article-title":"Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom","volume":"140","author":"Battersby","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706065532400_uxag003-B2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2008.07.050","article-title":"Chronic granulomatous disease as a risk factor for autoimmune disease","volume":"122","author":"De Ravin","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706065532400_uxag003-B3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10875-007-9160-5","article-title":"Inflammatory manifestations in chronic granulomatous disease (CGD)","volume":"28","author":"Rosenzweig","year":"2008","journal-title":"J Clin Immunol"},{"key":"2026041706065532400_uxag003-B4","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/pde.12826","article-title":"Association between discoid lupus erythematosus and chronic granulomatous disease-report of two cases and review of the literature","volume":"33","author":"Xie","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"2026041706065532400_uxag003-B5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/art.1780340116","article-title":"Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature","volume":"34","author":"Manzi","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2026041706065532400_uxag003-B6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2249.2007.03321.x","article-title":"Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology","volume":"148","author":"Cale","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2026041706065532400_uxag003-B7","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/jpids\/piy014","article-title":"Noninfectious manifestations and complications of chronic granulomatous disease","volume":"7","author":"Henrickson","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2026041706065532400_uxag003-B8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1542\/peds.114.2.462","article-title":"Gastrointestinal involvement in chronic granulomatous disease","volume":"114","author":"Marciano","year":"2004","journal-title":"Pediatrics"},{"key":"2026041706065532400_uxag003-B9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2014.04.014","article-title":"Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease","volume":"134","author":"Magnani","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706065532400_uxag003-B10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/ciw837","article-title":"Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France","volume":"64","author":"Dunogu\u00e9","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026041706065532400_uxag003-B11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10875-019-00661-0","article-title":"Myriad faces of chronic granulomatous disease: all in an Indian family with novel CYBB defect","volume":"39","author":"Vignesh","year":"2019","journal-title":"J Clin Immunol"},{"key":"2026041706065532400_uxag003-B12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaip.2020.11.041","article-title":"Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease\u2014single-center experience from North India","volume":"9","author":"Vignesh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026041706065532400_uxag003-B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.gendis.2019.07.010","article-title":"Recent advances in chronic granulomatous disease","volume":"7","author":"Anjani","year":"2020","journal-title":"Genes Dis"},{"key":"2026041706065532400_uxag003-B14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2019.04.014","article-title":"Tamoxifen restores extracellular trap formation in neutrophils from patients with chronic granulomatous disease in a reactive oxygen species\u2013independent manner","volume":"144","author":"Sharma","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706065532400_uxag003-B15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"key":"2026041706065532400_uxag003-B16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026041706065532400_uxag003-B17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFN\u03b1 and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026041706065532400_uxag003-B18","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/0961203320965699","article-title":"SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus","volume":"29","author":"Stuckrad","year":"2020","journal-title":"Lupus"},{"key":"2026041706065532400_uxag003-B19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"key":"2026041706065532400_uxag003-B20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026041706065532400_uxag003-B21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10875-013-9963-5","article-title":"Chronic granulomatous disease: two decades of experience from a tertiary care centre in North West India","volume":"34","author":"Rawat","year":"2014","journal-title":"J Clin Immunol"},{"key":"2026041706065532400_uxag003-B22","doi-asserted-by":"crossref","first-page":"625320","DOI":"10.3389\/fimmu.2021.625320","article-title":"Clinical, immunological, and molecular profile of chronic granulomatous disease: a multi-centric study of 236 patients from India","volume":"12","author":"Rawat","year":"2021","journal-title":"Front Immunol"},{"key":"2026041706065532400_uxag003-B23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10875-021-01148-7","article-title":"Utility of immunohistochemistry and immunofluorescence in determining the pathogenic variants of chronic granulomatous disease","volume":"42","author":"Sekar","year":"2022","journal-title":"J Clin Immunol"},{"key":"2026041706065532400_uxag003-B24","doi-asserted-by":"crossref","first-page":"uxaf018","DOI":"10.1093\/cei\/uxaf018","article-title":"Type I interferon signature: a quantitative standardized method for clinical application","volume":"219","author":"Tesser","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"2026041706065532400_uxag003-B25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026041706065532400_uxag003-B26","doi-asserted-by":"crossref","first-page":"905960","DOI":"10.3389\/fimmu.2022.905960","article-title":"Assessment of type I interferon signatures in undifferentiated inflammatory diseases: a Japanese multicenter experience","volume":"13","author":"Miyamoto","year":"2022","journal-title":"Front Immunol"},{"key":"2026041706065532400_uxag003-B27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026041706065532400_uxag003-B28","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1474-4422(24)00263-1","article-title":"CNS disease associated with enhanced type I interferon signalling","volume":"23","author":"Crow","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026041706065532400_uxag003-B29","first-page":"21","article-title":"The importance of the type I interferon system in autoimmunity","volume":"34","author":"Ronnblom","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2026041706065532400_uxag003-B30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1089\/ars.2013.5828","article-title":"Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature","volume":"21","author":"Kelkka","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2026041706065532400_uxag003-B31","doi-asserted-by":"crossref","first-page":"101118","DOI":"10.1016\/j.gendis.2023.101118","article-title":"Spontaneous NETosis and type I IFN signaling activation in resting neutrophils of chronic granulomatous disease patients with CYBB mutations","volume":"11","author":"Lu","year":"2024","journal-title":"Genes Dis"},{"key":"2026041706065532400_uxag003-B32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1189\/jlb.3MA0916-411R","article-title":"Human blood monocytes are able to form extracellular traps","volume":"102","author":"Granger","year":"2017","journal-title":"J Leukoc Biol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxag003\/66487041\/uxag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag003\/68104302\/uxag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag003\/68104302\/uxag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:07:11Z","timestamp":1776420431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxag003\/8432246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxag003","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"uxag003"}}